EFTR (eEFFECTOR Therapeutics, Inc.) שולי הרווח הגולמי

EFTR (eEFFECTOR Therapeutics Inc.) - סמל מסחרי של החברה

Geopolitical instability and logistics disruptions are slowing the procurement of biomaterials, as confirmed by the gross margin coefficient, where the parameter value equals 0.00. eFFECTOR Therapeutics (EFTR) focuses on developing selective inhibitors for lung cancer therapy. Simultaneously, the company is optimizing molecule time-to-market by delegating early-stage trials to external CRO networks to eliminate operational risks.

eEFFECTOR (EFTR): רווחיות לפי רווח גולמי מ-04.07.2022 עד 04.08.2024

פילוחים אנליטיים ודוחות נתונים של חברת eFFECTOR Therapeutics (EFTR)

- מדדי הערכת שווי שוק של העסק:
ניתוח מסכם של החברה:eEFFECTOR Therapeutics Inc. (EFTR)
מוצר ממותג של eEFFECTOR

The operational efficiency of eFFECTOR Therapeutics (EFTR) is reflected in the gross margin distribution, which demonstrates the profit share after deducting direct production costs. This indicator measures the difference between revenue and the cost of goods sold, allowing for an assessment of the fundamental profitability of each product unit. For a biotechnology business, this will serve as a key metric for measuring the commercialization efficiency of drugs targeting lung and breast cancer.